Skip to main content

Table 1 Baseline characteristics of all patients; comparison of insured and uninsured patients

From: Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study

Baseline characteristics Patients, N SVR, N Uninsured, N Insured, N P a
(% of all patients) (% of group) (% of uninsured) (% of insured)
All patients 512 459 (90) 289 (56) 223 (44) NS
Sex, Male 288 (56) 252 (88) 158 (55) 130 (58) NS
Race      **
 White 185 (36) 161 (87) 114 (39) 71 (32)  
 Black 223 (44) 200 (90) 107 (37) 116 (52)  
 Hispanic 81 (16) 76 (94) 50 (17) 31 (14)  
 Other 23 (5) 22 (96) 18 (6) 5 (2)  
Age, Median (interquartile range) 58 (54–62) NA 57 (53–61) 59 (54–64) **
BMI, Median (interquartile range) 28 (25–33) NA 28 (25–33) 28 (25–34) NS
Treatment-experienced 80 (16) 75 (94) 36 (12) 44 (20) *
Cirrhosis 262 (51) 227 (87) 133 (46) 129 (58) *
 Decompensated 56 (11) 46 (82) 27 (9) 29 (13) NS
HCV genotype      NS
 Genotype 1a 309 (60) 273 (88) 168 (58) 141 (63)  
 Genotype 1b 99 (19) 91 (92) 54 (19) 45 (20)  
 Genotype 2 45 (9) 41 (91) 25 (9) 18 (8)  
 Genotype 3 30 (6) 27 (90) 23 (8) 7 (3)  
 Other genotypes 29 (6) 29 (100) 19 (7) 10 (4)  
Treatment regimen      NS
 SOF + RBV 52 (10) 46 (88) 30 (10) 22 (10)  
 SMV + SOF ± RBV 48 (9) 39 (81) 21 (7) 27 (12)  
 DCV + SOF ± RBV 26 (5) 23 (88) 15 (5) 11 (5)  
 LDV + SOF ± RBV 355 (69) 323 (91) 214 (74) 141 (63)  
 OBV + PTV/r + DSV ± RBV 27 (5) 24 (89) 7 (2) 20 (9)  
 EBR + GZR 4 (1) 4 (100) 2 (1) 2 (1)  
HIV co-infected 54 (11) 47 (87) 21 (7) 33 (15) **
Chronic HBV 15 (3) 14 (93) 7 (2) 8 (4) NS
Liver or kidney transplant 23 (4) 20 (87) 9 (3) 14 (6) NS
History of alcohol abuse 208 (41) 183 (88) 109 (38) 99 (44) NS
History of drug abuse 255 (50) 226 (89) 141 (49) 114 (51) NS
History of mental health disorder 194 (38) 172 (89) 113 (39) 81 (36) NS
  1. a P value of uninsured versus insured by χ2 test for categorical variables and Mann–Whitney test for continuous variables; *P < 0.05; **P < 0.01
  2. BMI body mass index, HCV hepatitis C virus, Other genotypes genotypes 4 & 6 or patients infected with one or more genotypes, SOF sofosbuvir, RBV ribavirin, SMV simeprevir, DCV daclatasvir, LDV ledipasvir, OBV ombitasvir, PTV/r ritonavir-boosted paritaprevir, DSV dasabuvir, EBR elbasivr, GZR grazoprevir, HIV human immunodeficiency virus, HBV hepatitis B virus infection, SVR sustained virologic response, NA not available, NS not significant